相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate
Yumin Hu et al.
BLOOD (2010)
PML-RARα/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia
Joost H. A. Martens et al.
CANCER CELL (2010)
The Combination of a Histone Deacetylase Inhibitor with the Bcl-2 Homology Domain-3 Mimetic GX15-070 Has Synergistic Antileukemia Activity by Activating Both Apoptosis and Autophagy
Yue Wei et al.
CLINICAL CANCER RESEARCH (2010)
Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
Sean J. Whittaker et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Histone deacetylases: salesmen and customers in the post-translational modification market
Andre Brandl et al.
BIOLOGY OF THE CELL (2009)
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies
Tamer E. Fandy et al.
BLOOD (2009)
Preclinical Studies of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytosine Arabinoside and Etoposide for Treatment of Acute Leukemias
Ken Shiozawa et al.
CLINICAL CANCER RESEARCH (2009)
A phase 2 study of vorinostat in acute myeloid leukemia
Eric W. Schaefer et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
MECHANISMS OF DISEASE Cell Death
Richard S. Hotchkiss et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells
Warren Fiskus et al.
BLOOD (2008)
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
Guillermo Garcia-Manero et al.
BLOOD (2008)
Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs
Kei-ichi Ozaki et al.
CANCER SCIENCE (2008)
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma
Leigh Ellis et al.
CLINICAL CANCER RESEARCH (2008)
Isoform-Selective Histone Deacetylase Inhibitors
Takayoshi Suzuki et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo
Marielle Fournel et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions
Roberto R. Rosato et al.
MOLECULAR CANCER THERAPEUTICS (2008)
DNA methyltransferase and histone deacetylase inhibitors in the treatment of Myelodysplastic syndromes
Elizabeth A. Griffiths et al.
SEMINARS IN HEMATOLOGY (2008)
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
Guillermo Garcia-Manero et al.
BLOOD (2008)
Progress in the treatment of acute myeloid leukemia
Farhad Ravandi et al.
CANCER (2007)
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome
Andres O. Soriano et al.
BLOOD (2007)
Histone deacetylase inhibitors: molecular mechanisms of action
W. S. Xu et al.
ONCOGENE (2007)
被撤回的出版物: Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation (Retracted article. See vol. 78, pg. 4097, 2018)
Chang-Shi Chen et al.
CANCER RESEARCH (2007)
Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
Elihu Estey et al.
BLOOD (2007)
FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
ONCOLOGIST (2007)
Reliability design of vehicle components with arbitrary distribution parameters
Y. Zhang et al.
INTERNATIONAL JOURNAL OF AUTOMOTIVE TECHNOLOGY (2006)
Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia
Guillermo Garcia-Manero et al.
BLOOD (2006)
Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor
Weisheng Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia
Giuseppe Cimino et al.
CANCER RESEARCH (2006)
Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor
Blanca Sanchez-Gonzalez et al.
BLOOD (2006)
Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of γ-H2AX foci
Anupama Munshi et al.
MOLECULAR CANCER THERAPEUTICS (2006)
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies
Francis Giles et al.
CLINICAL CANCER RESEARCH (2006)
Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: A mechanism for leukemia-specific HDI-dependent apoptosis?
Terry J. Gaymes et al.
MOLECULAR CANCER RESEARCH (2006)
Histone deacetylase inhibitors enhance phosphorylation of histone H2AX after ionizing radiation
Yubin Zhang et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome - Predictive prognostic models for outcome
H Kantarjian et al.
CANCER (2006)
The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination moth all-trans retinoic acid in patients with acute myeloid leukemia
A Kuendgen et al.
CANCER (2006)
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
S Minucci et al.
NATURE REVIEWS CANCER (2006)
Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia
G Bug et al.
CANCER (2005)
Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia
A Kuendgen et al.
ANNALS OF HEMATOLOGY (2005)
Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim
Y Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Modulating molecular chaperone Hsp90 functions through reversible acetylation
S Aoyagi et al.
TRENDS IN CELL BIOLOGY (2005)
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90 - A novel basis for antileukemia activity of histone deacetylase inhibitors
P Bali et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells
MR Trus et al.
LEUKEMIA (2005)
Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid
C Pilatrino et al.
CANCER (2005)
Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies
KN Bhalla
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
WK Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin
AR Robbins et al.
CELL CYCLE (2005)
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer
MF Fraga et al.
NATURE GENETICS (2005)
Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors
MJ Peart et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia
JC Byrd et al.
BLOOD (2005)
Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors
JS Ungerstedt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells
A Nebbioso et al.
NATURE MEDICINE (2005)
Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway
A Insinga et al.
NATURE MEDICINE (2005)
Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis
IV Gregoretti et al.
JOURNAL OF MOLECULAR BIOLOGY (2004)
Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1
CY Gui et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid
A Kuendgen et al.
BLOOD (2004)
Apoptotic and autophagic cell death induced by histone deacetylase inhibitors
YF Shao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Histone hyperacetylation in mitosis prevents sister chromatid separation and produces chromosome segregation defects
D Cimini et al.
MOLECULAR BIOLOGY OF THE CELL (2003)
Histone deacetylases
PA Marks et al.
CURRENT OPINION IN PHARMACOLOGY (2003)
Histone acetylation-mediated regulation of genes in leukaemic cells
AE Chambers et al.
EUROPEAN JOURNAL OF CANCER (2003)
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
M Göttlicher et al.
EMBO JOURNAL (2001)
Histone deacetylases and cancer: Causes and therapies
PA Marks et al.
NATURE REVIEWS CANCER (2001)
The promise of retinoids to fight against cancer
L Altucci et al.
NATURE REVIEWS CANCER (2001)
The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species
AA Ruefli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites
LL Huang et al.
ONCOGENE (2000)
Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells
L Qiu et al.
MOLECULAR BIOLOGY OF THE CELL (2000)
分享论文
